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Monoaminergic neurotransmitters are released into the
synaptic cleft by exocytosis; sodium chloride-dependent
monoamine transporters like the serotonin transporter
(SERT) efficiently clear the synapse of serotonin to stop
neurotransmission. Administration of amphetamines
(AMPH), induces the reversal of substrate transport. It has
been repeatedly shown that inward and outward transport
can be independently regulated; phosphorylation of key
residues in the amino-terminus is thought to be the
responsible mechanism. In our study, we provide evi-
dence for a novel intracellular regulation mechanism of
SERT. Depletion of phosphatidylinositol-4,5-bisphos-
phate (PIP2) reduced AMPH-induced SERT-mediated
substrate release specifically. This effect was limited to
SERT-mediated efflux because SERT-mediated reuptake
was completely unaffected. PIP2 depletion was achieved
by activation of phospholipase C (PLC) upon application
of 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benze-
nesulfonamide (m-3M3FBS; 25 μM), a direct and potent
PLC activator. Efflux was determined in a superfusion sys-
tem that allows for measurement of AMPH-triggered frac-
tional release rates of substrate efflux. Preincubation (10
min) of SERT wild-type-expressing cells with m-3M3FBS
led to a significant and concentration-dependent reduc-
tion of AMPH-induced efflux. This effect was largely
blocked by co-application of U73122 (5 μM; 2 min), a
PLC inhibitor. PLC-mediated PIP2 hydrolysation gener-
ates inositol-3-phosphate and diacylglycerol and thereby
provides downstream effects like protein kinase C (PKC)
activation and intracellular calcium rise. Thus we (i) stim-
ulated PKC with PMA (1.0 μM; 10 min), (ii) inhibited
with GF109203X (1.0 μM; 10 min) and (iii) chelated Ca2+
with BAPTA-AM (50 μM; 30 min): There was no effect on
efflux with or without m-3M3FBS. This strongly supports
the notion that the presence of PIP2 in the immediate
vicinity of SERT is essential for the AMPH-induced SERT-
mediated efflux. HEK cells endogenously express P2Y
receptors which activate PLC by Gqα. Stimulation of these
receptors with ATP and ADP (under suppression of phos-
phatidylinositol-4-kinase by 30 μM phenylarsineoxide)
showed a reduction of release. The trafficking process of
SERT was excluded by fluorescence confocal experiments
upon administration of m-3M3FBS. Perforated patch-
clamp recordings on hSERT-expressing HEK cells using m-
3M3FBS and PCA showed a significant reduction of mem-
brane current effects compared to control. Additionally,
these results provide evidence for the necessity of the pres-
ence of PIP2 in the plasma membrane for the AMPH-
induced outward configuration of SERT.
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